[go: up one dir, main page]

WO2002028999A3 - Profils d'expression genique dans les cellules granulocytaires - Google Patents

Profils d'expression genique dans les cellules granulocytaires Download PDF

Info

Publication number
WO2002028999A3
WO2002028999A3 PCT/US2001/030821 US0130821W WO0228999A3 WO 2002028999 A3 WO2002028999 A3 WO 2002028999A3 US 0130821 W US0130821 W US 0130821W WO 0228999 A3 WO0228999 A3 WO 0228999A3
Authority
WO
WIPO (PCT)
Prior art keywords
gene expression
expression profiles
granulocytic cells
drug
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/030821
Other languages
English (en)
Other versions
WO2002028999A2 (fr
Inventor
Yasmin Beazer-Barclay
Sherman M Weissman
Shigeru Yamaga
Joseph Vockley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ore Pharmaceuticals Inc
Original Assignee
Ore Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ore Pharmaceuticals Inc filed Critical Ore Pharmaceuticals Inc
Priority to AU21265/02A priority Critical patent/AU2126502A/en
Publication of WO2002028999A2 publication Critical patent/WO2002028999A2/fr
Publication of WO2002028999A3 publication Critical patent/WO2002028999A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne l'identification de modifications globales survenant dans l'expression génique associée à l'activation des granulocytes, ainsi que l'identification de profils d'expression utiles en tant que marqueurs de diagnostic et marqueurs susceptibles d'être utilisés pour contrôler l'état et la progression de maladies, ou la toxicité, l'efficacité et le métabolisme de médicaments
PCT/US2001/030821 2000-10-03 2001-10-03 Profils d'expression genique dans les cellules granulocytaires Ceased WO2002028999A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU21265/02A AU2126502A (en) 2000-10-03 2001-10-03 Gene expression profiles in granulocytic cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23718900P 2000-10-03 2000-10-03
US60/237,189 2000-10-03

Publications (2)

Publication Number Publication Date
WO2002028999A2 WO2002028999A2 (fr) 2002-04-11
WO2002028999A3 true WO2002028999A3 (fr) 2002-08-22

Family

ID=22892687

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/030821 Ceased WO2002028999A2 (fr) 2000-10-03 2001-10-03 Profils d'expression genique dans les cellules granulocytaires

Country Status (2)

Country Link
AU (1) AU2126502A (fr)
WO (1) WO2002028999A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7628989B2 (en) 2001-04-10 2009-12-08 Agensys, Inc. Methods of inducing an immune response

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7026121B1 (en) 2001-06-08 2006-04-11 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US7235358B2 (en) 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
ITMI20011465A1 (it) 2001-07-10 2003-01-10 Novuspharma Spa Gene ad attivita' oncosoppressiva
US7112410B1 (en) 2001-08-29 2006-09-26 Human Genome Sciences, Inc. Human tumor necrosis factor TR21 and methods based thereon
WO2003023007A2 (fr) 2001-09-07 2003-03-20 Bristol-Myers Squibb Company Polynucleotide codant pour un recepteur lie a une nouvelle proteine g humaine, hgprmby39
EP1440160A4 (fr) * 2001-10-31 2005-04-20 Millennium Pharm Inc Procedes et compositions pour le traitement et le diagnostic de dereglements cellulaires proliferants a base de 32222
MXPA05002818A (es) * 2002-09-19 2005-08-16 Tanox Inc Receptor del factor nuclear de celulas t activadas.
US20040121375A1 (en) * 2002-09-30 2004-06-24 Bayer Pharmaceuticals Corporation Methods for prediction and prognosis of cancer, and monitoring cancer therapy
US7189524B1 (en) 2002-11-25 2007-03-13 Amgen, Inc. Receptor ligands and methods of modulating receptors
EP2314676A1 (fr) * 2002-11-26 2011-04-27 Genentech, Inc. Compositions et procédés pour le traitement de maladies liées au système immunitaire
AU2002952993A0 (en) * 2002-11-29 2002-12-12 The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland Therapeutic and diagnostic agents
AU2003900639A0 (en) * 2003-02-12 2003-02-27 G2 Therapies Ltd Novel method of treating inflammatory diseases
EP1605044A4 (fr) * 2003-03-10 2006-12-06 Japan Science & Tech Agency Marqueur pour detecter une cellule souche mesenchymateuse et procede pour distinguer une cellule souche mesenchymateuse au moyen d'un marqueur
US7659077B2 (en) 2003-03-17 2010-02-09 Riikka Lund Methods utilizing target genes related to immune-mediated diseases
WO2005019258A2 (fr) * 2003-08-11 2005-03-03 Genentech, Inc. Compositions et methodes de traitement de maladies relatives au systeme immunitaire
TW200517503A (en) * 2003-09-10 2005-06-01 Japan Science & Tech Agency Group of genes differentially expressed in peripheral blood cells and diagnostic method and assay method using the same
WO2005035746A2 (fr) * 2003-10-02 2005-04-21 Xantos Biomedicine Ag Usage medical de tbk-1 ou d'inhibiteurs de celui-ci
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
US20080193923A1 (en) * 2004-06-14 2008-08-14 Anne Philippi Human Obesity Susceptibility Gene Encoding a Potassium Voltage-Gated Channel and Uses Thereof
FI20041204A0 (fi) 2004-09-16 2004-09-16 Riikka Lund Menetelmät immuunivälitteisiin sairauksiin liittyvien uusien kohdegeenien hyödyntämiseksi
EP1851543A2 (fr) 2005-02-24 2007-11-07 Compugen Ltd. Nouveaux marqueurs diagnostiques, en particulier pour l'imagerie in vivo, et dosage et procédés d'utilisation associés
KR100822181B1 (ko) * 2006-05-09 2008-04-17 크레아젠 주식회사 Ｍｌｎ５１ 유전자 또는 단백질의 신규한 용도
ES2325711B1 (es) 2007-04-17 2010-06-17 Centro De Investigaciones Energeticas, Medioambientales Y Tecnologicas (Ciemat) Vectores de expresion que comprenden el promotor del gen pklr humano y su uso para la elaboracion de composiciones farmaceuticas destinadas a terapia genica somatica con expresion especifica en celulas eritroides.
CA2878025C (fr) 2008-01-18 2018-12-11 President And Fellows Of Harvard College Procedes de detection de signatures d'une maladie ou d'etats dans des fluides corporels
WO2010062960A2 (fr) 2008-11-26 2010-06-03 Cedars-Sinai Medical Center Méthodes de détermination d'une réceptivité à une thérapie par anti-tnfα lors d’une maladie intestinale inflammatoire
CA2806304A1 (fr) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methodes de depistage de maladies ou d'affections prenatales ou liees a la grossesse
EP2596116A4 (fr) 2010-07-23 2014-03-19 Harvard College Procédés de détection de maladies/pathologies auto-immunes ou liées au système immunitaire
FR2981662A1 (fr) * 2011-10-20 2013-04-26 Assist Publ Hopitaux De Paris Methode de quantification de marqueurs renaux par dosage urinaire.
NZ771629A (en) 2013-03-09 2022-12-23 Harry Stylli Methods of detecting cancer
CN112870368A (zh) 2013-03-27 2021-06-01 西达-赛奈医疗中心 通过抑制tl1a的功能和相关信号传导途径来减轻并逆转纤维化和炎症
WO2015010108A1 (fr) 2013-07-19 2015-01-22 Cedars-Sinai Medical Center Signature de la voie de signalisation de tl1a (tnfsf15)
CN118773299A (zh) 2016-03-17 2024-10-15 西达-赛奈医疗中心 通过rnaset2诊断炎性肠病的方法
WO2019226611A1 (fr) 2018-05-22 2019-11-28 Ionis Pharmaceuticals, Inc. Modulateurs de l'expression d'apol1
WO2022064163A1 (fr) * 2020-09-22 2022-03-31 The Secretary Of State For Defence Appareils, kits et procédés pour prédire le développement d'une septicémie

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CAO ET AL.: "Expression of plasma platelet-activating factor acetylhydrolase is transcriptionally regulated by mediators of inflammation", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 7, 13 February 1998 (1998-02-13), pages 4012 - 4020, XP002950596 *
WINZEN ET AL.: "The p38 MAP kinase pathway signals for cytokine-induced mRNA stabilization via MAP kinase-activated protein kinase 2 and an AU-rich region-targeted mechanism", THE EMBO JOURNAL, vol. 18, no. 18, 1999, pages 4969 - 4980, XP002950595 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7628989B2 (en) 2001-04-10 2009-12-08 Agensys, Inc. Methods of inducing an immune response
US7641905B2 (en) 2001-04-10 2010-01-05 Agensys, Inc. Methods of inducing an immune response

Also Published As

Publication number Publication date
AU2126502A (en) 2002-04-15
WO2002028999A2 (fr) 2002-04-11

Similar Documents

Publication Publication Date Title
WO2002028999A3 (fr) Profils d'expression genique dans les cellules granulocytaires
WO2004089396A3 (fr) Composes antifongiques et leurs procedes de mise en oeuvre
WO2002029103A3 (fr) Profils d'expression genetique dans le cancer du foie
WO2006138418A3 (fr) Amelioration de la performance cognitive avec des activateurs de sirtuine
TW200700406A (en) Novel thiophene derivatives
WO2006012527A8 (fr) Groupes de liaison bivalents et conjugués de ceux-ci
TW200716591A (en) Novel thiophene derivatives
WO2006108075A3 (fr) Compositions et methodes accroissant la sensibilite aux medicaments et traitant les infections et maladies presentant une resistance aux medicaments
SI1673352T1 (sl) Sulfoksiminsko substituirani pirimidini kot CDK-in/ali VEGF-inhibitorji, njihova priprava in uporaba kot zdravila
TW200716552A (en) Novel thiophene derivatives
CL2007002017A1 (es) Compuestos derivados de [4,5']-bipirimidinil-6,4'-diamina; composicion farmaceutica; y uso como inhibidor de la actividad de cinasa en cancer de vejiga, cancer cervical y mieloma multiple.
WO2006035237A3 (fr) Procedes et compositions lies a la maladie d'alzheimer
TW200738670A (en) Novel thiophene derivatives
WO2007066150A3 (fr) Administration de principes actifs par voie transdermique pour l'obtention d'un effet systemique
AUPQ879500A0 (en) Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
BRPI0412989A (pt) combinação farmacêutica útil para mobilização de célula-tronco
ITMI20031396A1 (it) Composizione per uso farmaceutico o dietetico o cosmetico dotata di attivita' antiossidante.
ITRM20030363A0 (it) Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico diesse.
WO2007016352A3 (fr) Compositions orales liquides de losartan
WO2006122046A3 (fr) Therapies pour maladies vasculaires
WO2006060171A3 (fr) Procedes et compositions associes a des ensembles phage-nanoparticule
WO2006056696A3 (fr) 2-alcoxy-3,4,5-trihydroxy-alkylamides, leur preparation, compositions les contenant et utilisation
WO2006097617A3 (fr) Nouveaux derives dihydropyrimidines et leur utilisation comme agents anti-cancereux
RU2005111873A (ru) Средство с антикоагулянтной, антитромбоцитарной, антитромботической фибриндеполимеризационной и фибринолитической активностями
NL1022442C2 (nl) Toepassing van lipide ter verbetring van de opname van nutrienten en (farmaceutisch) actieve stoffen.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP